Selected-GenAtlas references SOURCE GeneCards NCBI Gene Swiss-Prot Ensembl
HGNC UniGene Nucleotide OMIM UCSC
Home Page
FLASH GENE
Symbol UBD contributors: mct/pgu - updated : 09-07-2016
HGNC name ubiquitin D
HGNC id 18795
Location 6p22.1      Physical location : 826.391 - 29.527.702
Synonym name
  • FAT10 protein,ubiquitin-like (HLA-F associated transcript)
  • diubiquitin
  • HLA-F-adjacent transcript 10
  • HLA-F-Associated Transcript 10
  • Synonym symbol(s) FAT10, UBD-3, DADB-115L1.4, GABBR1-3
    DNA
    TYPE functioning gene
    STRUCTURE 4.31 kb     2 Exon(s)
    10 Kb 5' upstream gene genomic sequence study
    MAPPING cloned Y linked   status confirmed
    Map see MHC1
    RNA
    TRANSCRIPTS type messenger
    identificationnb exonstypebpproduct
    ProteinkDaAAspecific expressionYearPubmed
    2 - 1006 18 165 - 2005 15831455
    EXPRESSION
    Type widely
       expressed in (based on citations)
    organ(s)
    SystemOrgan level 1Organ level 2Organ level 3Organ level 4LevelPubmedSpeciesStageRna symbol
    Cardiovascularheart   highly Homo sapiens
    Digestiveliver   highly
     stomach   highly
    Lymphoid/Immunethymus   highly Homo sapiens
    tissue
    SystemTissueTissue level 1Tissue level 2LevelPubmedSpeciesStageRna symbol
    Blood / Hematopoietic    
    Lymphoid    
    cells
    SystemCellPubmedSpeciesStageRna symbol
    Lymphoid/ImmuneB cell
    cell lineage some lymphoblastoid lineages
    cell lines
    fluid/secretion
    at STAGE
    PROTEIN
    PHYSICAL PROPERTIES
    STRUCTURE
    motifs/domains
  • two ubiquitin-like domains UBL) that share 29 and 36 p100 sequence identity with ubiquitin, respectively , two tandem, head-to-tail, ubiquitin domains
  • C-terminal diglycine motif required for the formation of UBD conjugates, mediating its covalent binding to target proteins
  • HOMOLOGY
    Homologene
    FAMILY ubiquitin-like modifier family of proteins
    CATEGORY regulatory
    SUBCELLULAR LOCALIZATION extracellular
        intracellular
    intracellular,cytoplasm,organelle,membrane
    intracellular,cytoplasm,organelle,endoplasmic reticulum
    intracellular,nucleus,nucleolus
    basic FUNCTION
  • potential modulator of cell growth during B cell or dendritic cell development and activation
  • small ubiquitin-like modifier encoded in the major histocompatibility complex and ubiquitin-independent signal for proteasomal degradation
  • playing a role in epithelial apoptosis, which is an important component of the pathogenesis of many renal diseases
  • plays a role in the regulation of chromosomal stability
  • acting as a ubiquitin-independent but NUB1-dependent targeting signal for proteasomal degradation
  • mediates NF-kappaB activation and may promote tubulointerstitial inflammation in chronic kidney diseases
  • implicated in the regulation of diverse cellular processes, including mitosis, immune response, and apoptosis
  • ubiquitin-like that accelerate protein degradation through a ubiquitin-independent manner
  • new role in the pathogenesis of polyglutamine diseases
  • plays an important role in mediating the function of TNF during tumorigenesis by inducing cell cycle deregulation and chromosomal instability, and by inhibiting apoptosis
  • ubiquitin-like protein modifier that is induced in vertebrates following certain inflammatory stimuli
  • implicated in retinal cell biology and LCA (Leber congenital amaurosis) pathogenesis
  • by promoting the translocation of LRRFIP2 into cytoplasmic aggregates, UBD might block its recruitment to the membrane and its subsequent role in NFKB1 activation through TLR4 stimulation
  • is a cardioprotective protein
  • plays an important role in cell proliferation
  • cytokine-inducible ubiquitin-like modifier that directly targets UBD-conjugated proteins for degradation by the proteasome
  • is a novel modifier of thymic Ag presentation and epitope-dependent elimination of self-reactive T cells
  • attenuates DDX58 mediated antiviral signaling by segregating activated DDX58 from its signaling platform
  • only ubiquitin-like protein that can directly target substrates for degradation by proteasomes, but it can also stabilize the expression of certain substrates by antagonizing ubiquitination
  • stabilizes EEF1A1 expression to promote tumor proliferation in a complex manner
  • is involved in proteasomal degradation and antigen processing
  • unlike ISG15, ubiquitin and UBD are conjugated to a similar degree to newly translated and pre-existing proteins
  • UBD is a ubiquitin-like protein modifier that targets proteins for proteasomal degradation
  • CELLULAR PROCESS cell cycle, division, mitosis
    protein, degradation
    PHYSIOLOGICAL PROCESS immunity/defense
    text antimicrobial tumoral response
    PATHWAY
    metabolism
    signaling
    a component
    INTERACTION
    DNA
    RNA
    small molecule
    protein
  • non covalently binding to MAD2L1, a spindle checkpoint protein, during mitosis
  • binding partner of HDAC6, UBD serves as a signal for proteasomal degradation
  • USE1 is an interaction partner of UBD
  • in the nucleus was found co-localized with TP53 and altered its subcellular compartmentalization
  • binds preferably to huntingtin with a short pQ chain and completely aggregated huntingtin was UBD-negative
  • AIPL1 may have a role in directly regulating the UBD conjugation machinery
  • potential role of cytokine-induced UBD expression in regulating UBA6 pathways
  • UBA6 bound UBD with significantly higher affinity than ubiquitin
  • UBD and NUB1 both interact with PSMD4 via the VWA domain
  • inflammatory mediator LRRFIP2 is covalently modified by UBD
  • STAT3 binding stabilizes NFKB1 on the UBD promoter and leads to maximum induction of UBD gene expression
  • UBD play a role in mitotic regulation through its interaction with mitotic arrest-deficient 2 (MAD2L1)
  • UBA1 and UBD form a stable non-reducible conjugate under overexpression as well as under endogenous conditions after induction of endogenous UBD expression with proinflammatory cytokines
  • UBD conjugation, a post-translational modification analogous to ubiquitination, specifically requires UBA6 and UBE2Z as its activating (E1) and conjugating (E2) enzymes
  • UBD is a novel negative regulator of DDX58-mediated inflammatory response
  • UBD stabilizes the translation elongation factor EEF1A1 which contributes to cancer cell proliferation
  • novel function of LMO2 involving in the regulatory hierarchy of UBA6-USE1-FAT10ylation pathway by targeting the E1 enzyme UBA6
  • UBD appears to mitigate APOL1-mediated toxicity by targeting it for destruction
  • cell & other
    REGULATION
    activated by UBA6 (is exclusively activated by UBA6)
    induced by IFNG
    inducible by tumor necrosis factor alpha
    Other its degradation is accelerated after induction of apoptosis, suggesting that it plays a role in prosurvival pathways
    ASSOCIATED DISORDERS
    corresponding disease(s)
    Other morbid association(s)
    TypeGene ModificationChromosome rearrangementProtein expressionProtein Function
    tumoral     --over  
    in hepatocellular carcinoma and in several gastrointestinal and gynecological cancers
    constitutional     --over  
    in cells lead to increased mitotic nondisjunction and chromosome instability, and this effect is mediated by an abbreviated mitotic phase and the reduction in the kinetochore localization during the prometaphase stage of the cell cycle
    constitutional     --over  
    led to chromosomal instability that is mediated by an abbreviated mitotic phase
    constitutional     --over  
    in the heart at the border zone of myocardial infarction
    tumoral     --over  
    significantly correlated with poor survival in pancreatic ductal adenocarcinoma (PDAC) patients
    Susceptibility
    Variant & Polymorphism
    Candidate gene
    Marker
  • may be involved in gastric carcinogenesis, and is a potential marker for the prognosis of gastric cancer patients
  • Therapy target
    SystemTypeDisorderPubmed
    cancer  
    interaction of FAT10 with MAD2L1 is a key mechanism underlying the promalignant property of UBD and offer prospects for the development of anticancer strategies
    ANIMAL & CELL MODELS